Corrigendum to 'Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States' [Clinical Lymphoma, Myeloma, and Leukemia Volume 24, Issue 8, August 2024, Pages 523-530]
1 HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address: [email protected].
2 Yale University School of Medicine, New Haven, CT.
3 HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
4 Brigham and Women's Hospital, Department of Radiation Oncology, Boston, MA.
5 MD Anderson Cancer Center, Houston, TX.
6 Medstar/Georgetown-Washington Hospital Center, Washington, DC.
7 University of California Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA.
8 John Theurer Cancer Center, Hackensack, NJ.
9 Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC; Ohio State University Comprehensive Cancer Center, Columbus, OH.
10 Vanderbilt University Medical Center, Nashville, TN.
11 City of Hope Medical Center, Duarte, CA.
12 Ohio State University Comprehensive Cancer Center, Columbus, OH.
13 University of North Carolina, Chapel Hill, NC.
14 Medstar Georgetown University Hospital, Washington, DC.
15 Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC.
16 University Hospital Seidman Cancer Center, Cleveland, OH.
17 Dana-Farber Cancer Institute, Boston, MA.
18 John Stroger Cook County Hospital, Chicago, IL.
19 Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine & Michael E. DeBakey VA Medical Center, Houston, TX.
20 Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, USA.